Evotec (ETR:EVT) has been given a €20.00 ($23.26) target price by Berenberg Bank in a research report issued to clients and investors on Tuesday, March 5th. The brokerage currently has a “neutral” rating on the stock. Berenberg Bank’s price objective would suggest a potential downside of 5.62% from the company’s current price.
Other equities research analysts also recently issued research reports about the company. Deutsche Bank set a €21.00 ($24.42) target price on Evotec and gave the company a “buy” rating in a report on Thursday, November 8th. Oddo Bhf set a €26.00 ($30.23) target price on Evotec and gave the company a “buy” rating in a report on Thursday, November 15th.
Shares of EVT opened at €21.19 ($24.64) on Tuesday. Evotec has a 12-month low of €12.07 ($14.03) and a 12-month high of €23.36 ($27.16). The company has a debt-to-equity ratio of 38.36, a quick ratio of 1.03 and a current ratio of 1.16. The company has a market cap of $3.12 billion and a PE ratio of 50.45.
Evotec Company Profile
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services.
Recommended Story: What is Put Option Volume?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.